Zokhudza C-CAR031

C-CAR031 ndi mankhwala a autologous, okhala ndi zida za GPC3-target chimeric antigen receptor T-Cell (CAR-T) receptor, omwe akuphunziridwa pochiza HCC.

Kupita patsogolo kwa kafukufuku wa C-CAR031 mu khansa ya chiwindi (HCC) kunaperekedwa pakamwa pamsonkhano wapachaka wa American Society of Clinical Oncology (ASCO) womwe unachitikira ku Chicago mu 2024.

Njira: Kuyesa koyamba kwa kuchuluka kwa mlingo mwa anthu, kotseguka pogwiritsa ntchito njira yofulumira komanso kapangidwe ka i3+3. Madokotala a HCC apamwamba a GPC3+ omwe adalephera kulandira chithandizo cha mzere 1 adalandira njira imodzi yokha ya C-CAR031 post standard lymphodepletion. Mapeto ake ndi chitetezo ndi kulekerera, zina zimaphatikizapo pharmacokinetics ndi mphamvu yoyambirira. Zochitika zoyipa (AEs) zidayesedwa ndi CTCAE 5.0, ndipo cytokine release syndrome (CRS) / immune effector cell-associated neurotoxicity syndrome (ICANS) zidayesedwa motsatira njira ya ASTCT 2019. Yankho lolondola lidayesedwa ndi wofufuza motsatira RECIST 1.1.

Zotsatira: Pofika pa Januware 5, 2024, anthu 24 onse adalandira C-CAR031 infusion pa mlingo wa 4 dose (DLs). Anthu onse anali ndi BCLC stage C HCC, 83.3% (20/24) anali ndi metastasis ya extrahepatic. Chiwerengero chapakati cha mankhwala omwe adagwiritsidwa ntchito kale chinali 3.5 (range 1-6), anthu 23 (95.8%) adalandira ICIs (immunocheckpoint inhibitors) ndi TKIs (tyrosine kinase inhibitors). Anthu onse anali ndi chitetezo. Palibe poizoni woletsa mlingo ndipo ICANS idawonedwa. CRS idawonedwa m'magawo 22 (91.7%) ndi CRS imodzi (4.2%) yokha (G) 3. Ma AE odziwika kwambiri a ≥G3 anali lymphocytopenia (100%), neutropenia (70.8%), thrombocytopenia (37.5%) ndi transaminase elevation (16.7%). Gawo limodzi (4.2%) linali ndi G4 myelosuppression ndipo gawo limodzi (4.2%) linali ndi G3 interstitial pneumonitis pa DL4 yoyambitsidwa ndi G3 CRS. Ma AE onse anali osinthika. Ma pts 22 adawunikidwa kuti agwire ntchito. Kuchepa kwa chotupa kudawonedwa mu 90.9% pts, osati m'zilonda zamkati mwa chiwindi zokha komanso zomwe zili kunja kwa chiwindi ndi kuchepa kwapakati kwa 44.0% (range, 3.4%-94.4%). Chiŵerengero chowongolera matenda chinali 90.9% ndipo chiŵerengero choyankha (ORR) chinali 50.0% pa ma pts a ma DL onse. Mu DL4, ORR inali 57.1%.

Mapeto: Kafukufukuyu adawonetsa chitetezo chodalirika komanso kulimbikitsa ntchito yolimbana ndi chotupa ya C-CAR031 mwa odwala a HCC omwe adachiritsidwa kwambiri.

Pakadali pano, pali mayesero ambiri azachipatala a ukadaulo watsopano wothana ndi khansa ku China omwe akufuna odwala. Mukafunsira mankhwala ndi ukadaulo watsopano, mutha kulumikizana ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region.

Nambala ya Foni: 4008803716

Email：myimmnet@163.com

Zolemba

1.https://www.prnewswire.com/news-releases/abelzeta-announces-clinical-data-showing-preliminary-anti-tumor-activity-for-c-car031-an-armored-autologous-gpc3-car-t-in-patients-with-advanced-hepatocellular-carcinoma-at-asco-annual-meeting-2024-302162941.html

2.https://www.abelzeta.com/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/

3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019

4.ASCO-2024-IR-Presentation.pdf (astrazeneca.com)